drugset / Trial / NCT04129931

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931

RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.

Timeline

Start
2019-12-19
Primary completion
2025-02-19
Completion
2025-03-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Broncho-Vaxom Other / unclassified 7 mg Oral
Subject Cavosonstat Small molecule 50 mg Oral
Subject Clazakizumab Monoclonal antibody 6.25 mg Subcutaneous
Subject Clazakizumab Monoclonal antibody 12.5 mg Subcutaneous
Subject Imatinib Small molecule 400 mg Oral
Subject MCT Unknown 12.5 g

Indications